Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumococcal vaccine antibody response in immunosuppressed adults with inflammatory bowel disease
NL-OMON45696Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2016
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Prevnar 13 and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease (2 arms), sponsored by Amsterdam University Medical Center. Started Dec 2016; status: active, not recruiting.
02
Drugs
Prevnar 1323-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NL-OMON45696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45696.